AbbVie Inc. (ABBV) Gets Downgraded to Peer Perform From Outperform by Wolfe Research

Core Insights - AbbVie Inc. (NYSE:ABBV) is recognized as one of the best-performing pharmaceutical stocks in 2025 [1] - The company has faced a downgrade from Outperform to Peer Perform by Wolfe Research, indicating that current share prices reflect high expectations for its drugs Skyrizi and Rinvoq [1] - AbbVie denied involvement in acquisition talks with Revolution Medicines, countering previous reports of advanced discussions [2] - UBS initiated coverage of AbbVie with a Neutral rating, raising the price target from $220 to $240, suggesting the stock is fairly priced amid emerging competition for its immunology drugs [3] Company Overview - AbbVie Inc. is a research-based pharmaceutical company focused on developing and selling products for chronic diseases across various therapeutic areas, including oncology, gastroenterology, rheumatology, dermatology, and virology [4]